Dmitry Balyasny’s Cidara Therapeutics CDTX Stock Holding History

Dmitry Balyasny’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-672,890	Closed	-$149M	–	2942
2025 Q4	$149M	Buy	672,890 +475,330	+241%	+$76.8M	0.19%	109
2025 Q3	$18.9M	Buy	197,560 +80,361	+69%	+$5.13M	0.02%	739
2025 Q2	$5.71M	Buy	+117,199	New	+$2.82M	0.01%	1223
2018 Q2	–	Sell	-590	Closed	-$47K	–	1805
2018 Q1	$47K	Buy	+590	New	+$80.6K	﹤0.01%	1863

Dmitry Balyasny's CDTX Position: Q1 2026 in Review

Dmitry Balyasny sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 672,890 shares — an estimated $149M sold.

Dmitry Balyasny first reported a position in CDTX in Q1 2018 and held it in 4 quarters. The position peaked at $149M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Dmitry Balyasny reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 672,890 Cidara Therapeutics shares in Q1 2026, an estimated $149M.
Dmitry Balyasny first reported a position in Cidara Therapeutics in Q1 2018 and held it in 4 quarters.
Dmitry Balyasny's Cidara Therapeutics position peaked at $149M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.